TERN Latest Headlines

Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN), Qiagen (QGEN) and Standard BioTools (LAB)

at www.tipranks.com (Thu, 8-Jan 9:20 AM)

Truist Financial Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)

at www.tipranks.com (Thu, 8-Jan 8:05 AM)

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Terns Pharmaceuticals (TERN) and Abivax SA Sponsored ADR (ABVX)

at www.tipranks.com (Thu, 8-Jan 8:00 AM)

Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (AVR) and Terns Pharmaceuticals (TERN)

at www.tipranks.com (Thu, 8-Jan 4:41 AM)

TERN’s $650 Million Public Offering Boosts Research Ambitions—What Does the Upsized Deal Signal for Investors?

Market Chameleon (Wed, 10-Dec 10:34 AM)

Terns Launches $400 Million Public Offering to Accelerate TERN-701 Oncology Program

Market Chameleon (Tue, 9-Dec 7:31 AM)

Terns Pharmaceuticals’ Jefferies Conference Appearance Highlights Advancements in Oncology Portfolio

Market Chameleon (Mon, 17-Nov 11:19 AM)

Terns Pharmaceuticals Highlights Innovative Cancer Therapy at Jefferies Global Healthcare Conference

Market Chameleon (Mon, 17-Nov 9:27 AM)

TERN-701 Shows Unprecedented 75% Response Rate in Tough-to-Treat CML Patients—What Does This Mean for the Future of Leukemia Therapy?

Market Chameleon (Tue, 4-Nov 10:34 AM)

TERN-701 Achieves Unprecedented 64% MMR in Refractory CML—Safety and Efficacy Data Spotlight Game-Changer Potential

Market Chameleon (Mon, 3-Nov 9:52 AM)

TERN-701 Achieves 64% MMR at 24 Weeks in Tough-to-Treat CML Patients—ASH Presentation Highlights Potential Breakthrough

Market Chameleon (Mon, 3-Nov 9:40 AM)